Institutional Ownership Moon Lake Immunotherapeutics (MLTX)
This table provides information about the institutional ownership of Moon Lake Immunotherapeutics (MLTX). We have compiled data on the 124 institutions that hold shares in the stock, with a total of 58.2 Million shares, which have been reported (via 13F filing form) to have a value of $2.98 Billion.
| Holding | Report Date | shares Held | Holding Value (Reported) | Last Trade | Trade History |
|---|---|---|---|---|---|
|
Bvf Inc
San Francisco, CA |
Nov 14, 2024 Q3 2024 |
21,751,284
shares
|
$1.11 Billion
34.86% of portfolio
|
Q2 2022
New holding
|
|
|
Cormorant Asset Management, LP
Boston, MA |
Nov 14, 2024 Q3 2024 |
8,494,151
shares
|
$435 Million
30.01% of portfolio
|
Q4 2023
Added 4.32%
|
|
|
Price T Rowe Associates Inc
Baltimore, MD |
Nov 14, 2024 Q3 2024 |
2,980,249
shares
|
$152 Million
0.02% of portfolio
|
Q3 2024
Added 16.35%
|
|
|
Avoro Capital Advisors LLC
New York, NY |
Nov 14, 2024 Q3 2024 |
2,770,100
shares
|
$142 Million
2.1% of portfolio
|
Q3 2024
Added 0.0%
|
|
|
Ken Griffin
Citadel Advisors LLC | Chicago, Il
|
Nov 14, 2024 Q3 2024 |
2,322,971
shares
|
$119 Million
0.02% of portfolio
|
Q3 2024
Added 2.53%
|
|
|
Holocene Advisors, LP
New York, NY |
Nov 14, 2024 Q3 2024 |
1,585,167
shares
|
$81.1 Million
0.35% of portfolio
|
Q3 2024
Reduced 2.53%
|
|
|
Goldman Sachs Group Inc
New York, NY |
Nov 14, 2024 Q3 2024 |
1,495,831
shares
|
$76.5 Million
0.01% of portfolio
|
Q3 2024
Added 19.5%
|
|
|
Westfield Capital Management CO LP
Boston, MA |
Nov 12, 2024 Q3 2024 |
1,167,358
shares
|
$59.7 Million
0.28% of portfolio
|
Q3 2024
Added 4.45%
|
|
|
Marshall Wace, LLP
London, X0 |
Nov 14, 2024 Q3 2024 |
1,154,385
shares
|
$59.1 Million
0.08% of portfolio
|
Q3 2024
Added 5.07%
|
|
|
Federated Hermes, Inc.
Pittsburgh, PA |
Nov 13, 2024 Q3 2024 |
1,130,328
shares
|
$57.8 Million
0.13% of portfolio
|
Q3 2024
Added 0.17%
|
|
|
Alliancebernstein L.P.
New York, NY |
Nov 14, 2024 Q3 2024 |
998,140
shares
|
$51.1 Million
0.02% of portfolio
|
Q3 2024
Reduced 2.31%
|
|
|
Paradigm Biocapital Advisors LP
New York, NY |
Nov 14, 2024 Q3 2024 |
931,480
shares
|
$47.7 Million
1.69% of portfolio
|
Q3 2024
New holding
|
|
|
Pictet Asset Management Sa
Geneva 73, V8 |
Aug 10, 2023 Q2 2023 |
894,005
shares
|
$45.7 Million
0.05% of portfolio
|
Q2 2023
New holding
|
|
|
Fred Alger Management, LLC
New York, NY |
Nov 14, 2024 Q3 2024 |
666,574
shares
|
$34.1 Million
0.17% of portfolio
|
Q3 2024
Added 1.14%
|
|
|
Hood River Capital Management LLC
Palm Beach Gardens, FL |
Nov 14, 2024 Q3 2024 |
646,662
shares
|
$33.1 Million
0.6% of portfolio
|
Q3 2024
New holding
|
|
|
Nuveen Asset Management, LLC
Chicago, IL |
Nov 14, 2024 Q3 2024 |
580,789
shares
|
$29.7 Million
0.01% of portfolio
|
Q3 2024
Added 11.32%
|
|
|
Adage Capital Partners Gp, L.L.C.
Boston, MA |
Nov 14, 2024 Q3 2024 |
505,000
shares
|
$25.8 Million
0.05% of portfolio
|
Q3 2024
Reduced 72.33%
|
|
|
Polar Capital Holdings PLC
London, X0 |
Nov 14, 2024 Q3 2024 |
500,000
shares
|
$25.6 Million
0.15% of portfolio
|
Q3 2024
Reduced 26.27%
|
|
|
Camber Capital Management LP
Boston, MA |
Nov 14, 2024 Q3 2024 |
441,000
shares
|
$22.6 Million
0.71% of portfolio
|
Q3 2024
Added 24.23%
|
|
|
Voya Investment Management LLC
Atlanta, GA |
Nov 14, 2024 Q3 2024 |
409,203
shares
|
$20.9 Million
0.03% of portfolio
|
Q1 2024
Reduced 84.42%
|
|
|
Black Rock Inc.
New York, NY |
Aug 13, 2024 Q2 2024 |
392,024
shares
|
$20.1 Million
0.0% of portfolio
|
Q2 2024
Reduced 3.98%
|
|
|
Finepoint Capital LP
Boston, MA |
Nov 13, 2024 Q3 2024 |
388,835
shares
|
$19.9 Million
2.04% of portfolio
|
Q2 2024
Added 7.74%
|
|
|
Balyasny Asset Management LLC
Chicago, IL |
Nov 14, 2024 Q3 2024 |
360,200
shares
|
$18.4 Million
0.03% of portfolio
|
Q3 2024
Reduced 38.35%
|
|
|
Pictet Asset Management Holding Sa
Carouge, V8 |
Nov 12, 2024 Q3 2024 |
356,836
shares
|
$18.3 Million
0.02% of portfolio
|
Q3 2024
Added 3.18%
|
|
|
Bio Impact Capital LLC
Cambridge, MA |
Nov 12, 2024 Q3 2024 |
349,063
shares
|
$17.9 Million
2.75% of portfolio
|
Q3 2024
Added 1.7%
|